FDA Approves Oral Nilotinib Tablets for Ph+ CML

The U.S. Food and Drug Administration (FDA) has approved Cavhanza, orally disintegrating nilotinib tablets, marking a significant shift in the management of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

Developed by Cycle Pharmaceuticals in collaboration with Flex Pharma, this new formulation of the second-generation tyrosine kinase inhibitor (TKI) addresses long-standing challenges regarding drug-drug interactions and rigid administration requirements that have historically burdened both patients and oncology nursing teams.

Addressing the acid-reducing agent challenge

A primary hurdle in CML therapy has been the interaction between TKIs and acid-reducing agents. Traditional nilotinib formulations often require strict timing or outright avoidance of proton pump inhibitors (PPIs) and H₂ antagonists (H₂RAs) because these agents can significantly compromise treatment efficacy by altering drug solubility.

In the current clinical landscape, approximately 25% of patients are co-prescribed PPIs or H₂RAs to manage gastrointestinal symptoms. This new treatment was specifically engineered to overcome this barrier through improved solubility and dissolution rates. This allows patients to maintain necessary bioavailability even with the concomitant use of PPIs and H₂RAs, notably removing the timing restrictions that often complicate daily medication schedules.

Innovative formulation and dosing flexibility

The therapeutic advancement is rooted in the proprietary ElectroNanoSpray (ENS) platform technology. This platform utilizes electric-field forces in a non-thermal spray drying process to create fine, amorphous particles that enhance the drug’s performance. By reformulating the established nilotinib molecule, the developers have optimized dosing performance and bioavailability.

Beyond the biochemical improvements, the orally disintegrating tablet (ODT) format offers practical advantages. It can be taken with or without water, providing a versatile option for patients on the go. Furthermore, clinical trials demonstrated that the tablet has no food effect, meaning it can be administered without regard to meal times. This represents a departure from earlier nilotinib protocols that required specific fasting windows, thereby reducing the food-related burden and supporting more flexible daily routines.

Indications and clinical utility

The FDA has approved the tablets for two primary adult indications:

• Newly diagnosed patients with Ph+ CML in the chronic phase (CP).
• Patients in the chronic or accelerated phase (AP) who have demonstrated resistance or intolerance to prior therapies, including imatinib (Gleevec).

For oncology nurses, this approval provides another tool in the TKI armamentarium to tailor treatment to a patient's specific lifestyle and physiological needs. As Victoria Dickinson, Chief Product Officer at Cycle, noted in a news release, finding a treatment that fits a patient’s lifestyle is a critical, yet often stressful, step in the oncology journey.

Nursing considerations: safety and monitoring

While the approval offers enhanced flexibility, it carries the same rigorous safety profile as other nilotinib products, including a Boxed Warning for QT prolongation and sudden deaths.

Oncology nurses must be vigilant in monitoring and educating patients on the following:

• Cardiovascular Health: Nilotinib can prolong the QT interval. Nurses should ensure baseline ECGs are obtained, followed by an ECG on day seven and periodic monitoring thereafter, particularly after dose adjustments.
• Electrolyte Management: Patients must be monitored for hypokalemia or hypomagnesemia. These deficiencies must be corrected before and during treatment, as the treatment is contraindicated in patients with these conditions or long QT syndrome.
• Drug interactions: Beyond acid-reducing agents, nurses must screen for the use of strong CYP3A4 inhibitors and other QT-prolonging drugs, which should be avoided.
• Monitoring for adverse reactions: Common non-hematologic reactions include rash, pruritus, headache, nausea, and fatigue. Hematologic concerns include myelosuppression, specifically thrombocytopenia, neutropenia, and anemia.

Patient support and access

To assist with the transition to this new therapy, the drug will be supported by Cycle Vita, a dedicated patient support program. This program is designed to help patients navigate the complexities of rare disease treatment, though eligibility criteria may apply.

As the oncology community prepares for the upcoming launch of the treatment, the focus remains on improving adherence through innovation. By removing the barriers of food restrictions and acid-reducing agent interactions, this new formulation aims to empower patients to maintain their treatment regimens with fewer disruptions to their quality of life.

Reference:

1. CAVHANZA™ (nilotinib) Orally Disintegrating Tablets. Prescribing Information. Flex Pharma; 2026.